1Landscape of NAMs in Neuroscience
The drug development pipeline for central nervous system (CNS) disorders has historically been hampered by high attrition rates, limited translatability of traditional animal models, and the complexity of human brain biology. In response, regulatory agencies and research organizations are increasingly turning to New Approach Methodologies (NAMs)—a diverse set of tools that aim to replace, reduce, or refine animal use while providing more human-relevant data. The FDA has released a landmark document outlining a strategic, stepwise approach for transitioning from animal-based testing to validated NAMs, emphasizing the need for cross-sector collaboration and qualification of these methods for regulatory decision-making.
FDA's Stepwise Approach to NAMs Qualification The FDA's 2025 NAMs framework calls for a phased qualification process: first, demonstrating mechanistic relevance and reproducibility; second, validating against a reference set of human and animal data; and third, gaining acceptance for a specific context of use. This approach is particularly critical for CNS indications, where the translational gap between preclinical models and clinical outcomes remains wide. Teams facing similar bottlenecks often pair this approach with zebrafish anxiety model when moving from discovery into validation.
- NAMs encompass 2D and 3D in vitro systems, organ-on-chip platforms, computational models, and alternative in vivo models such as zebrafish.
- The FDA's New Approach Methodologies initiative (April 2025) provides a framework for the development and acceptance of NAMs across therapeutic areas.
- Neuroscience NAMs aim to capture human biology more directly, enabling earlier insights into disease mechanisms, drug efficacy, and potential safety liabilities.
- Integration of NAMs into CNS pipelines is expected to reduce attrition rates and accelerate the delivery of therapies for neurological conditions.
| NAMs Category | Key Features | Relevance to Neuroscience |
|---|---|---|
| 2D primary / iPSC-derived neurons | Human-specific, scalable, amenable to high-content imaging | Screening for neurotoxicity, synaptic function, and disease phenotypes |
| 3D brain organoids and spheroids | Recapitulate tissue architecture, cell–cell interactions, and regional identity | Modeling complex neurodevelopmental and neurodegenerative disorders |
| Organ-on-chip (BBB, brain microphysiological systems) | Dynamic flow, multi-cell type co-culture, functional readouts | Studying drug transport, neuroinflammation, and network activity |
| Zebrafish whole-organism assays | Genetic tractability, optical transparency, high fecundity, functional CNS circuits | Phenotypic screening, neurobehavioral assessment, and developmental neurotoxicity |
| Computational models (AI, in silico QSAR, physiologically based PK) | Predictive, integrative, data-driven | Hazard identification, dose–response prediction, and virtual clinical trials |
The NAMs landscape in neuroscience is rapidly evolving, with zebrafish models occupying a unique niche that bridges the gap between simple in vitro systems and complex mammalian models. The next sections examine how zebrafish-based assays are progressing from basic discovery to regulatory acceptance.
2Zebrafish Models at the Forefront
Zebrafish (Danio rerio) have emerged as a powerful vertebrate model for neuroscience research, combining the genetic tractability of invertebrate systems with the physiological complexity of a vertebrate CNS. Their optical transparency during early development, high fecundity, and rapid ex utero development make them ideally suited for high-throughput screening of neurological phenotypes. These attributes position zebrafish as a key component of the NAMs pipeline, particularly for studies that require whole-organism context without the ethical and logistical burdens of rodent models.
By leveraging these advantages, zebrafish models are increasingly being integrated into early drug discovery, safety pharmacology, and even regulatory toxicology studies. The ability to conduct a comprehensive neurological health evaluation in a single vertebrate system offers a cost-effective and human-relevant complement to traditional approaches.
3Established NAMs: Current Applications and Limitations
Established NAMs in neuroscience include 2D human iPSC-derived neuronal cultures, 3D brain organoids, and microelectrode array (MEA) platforms. These methods have been widely adopted for disease modeling, drug screening, and safety assessment. iPSC-derived neurons from patients have enabled the study of genetic forms of Alzheimer's, Parkinson's, and epilepsy, while brain organoids have recapitulated features of microcephaly and Zika virus-induced neurodevelopmental defects. However, these systems have limitations: 2D cultures lack the three-dimensional architecture and glial–neuronal interactions critical for complex CNS functions, and organoids often suffer from variability and lack of vascularization, limiting their reproducibility and scalability.
- iPSC-derived neurons and astrocytes are the most widely used NAMs in CNS drug discovery, with commercial assays available for high-content screening.
- Brain organoids have advanced to include region-specific identities (e.g., cortical, midbrain, hippocampal) and multi-region assembloids.
- MEA platforms provide functional readouts of neuronal network activity, enabling detection of seizure liability and pro-cognitive effects.
- Limitations include lack of systemic metabolism, blood–brain barrier (BBB) function, and immune interactions, which are particularly relevant for CNS drug disposition and efficacy.
Zebrafish Memory Model for Alzheimer's Drug Discovery
While established NAMs have proven valuable, their limitations underscore the need for complementary systems that can provide whole-organism biology with throughput. Zebrafish models fill this gap, and their use is expanding into areas traditionally dominated by rodents. In adjacent workflows, zebrafish memory model can support sample preparation and assay readouts without disrupting the core protocol.
4Emerging NAMs: Zebrafish-Based Assays Gaining Regulatory Recognition
Zebrafish-based assays are increasingly being recognized as valid NAMs for regulatory toxicology and safety pharmacology. The FDA's NAMs framework explicitly includes alternative vertebrate models, and zebrafish have been recommended by the Organisation for Economic Co-operation and Development (OECD) for developmental neurotoxicity testing. Recent advances include automated behavioral tracking systems (e.g., ZebraLab, DanioVision) that quantify locomotor activity, startle response, and social interaction, providing quantitative endpoints for CNS safety assessment. These assays are being used to detect seizure liability, motor impairment, and anxiety-like behavior, with data increasingly submitted as part of Investigational New Drug (IND) applications.
Regulatory Milestones for Zebrafish NAMs In 2023, the European Medicines Agency (EMA) accepted zebrafish embryo data for the assessment of potential developmental neurotoxicity for a CNS drug candidate, marking a significant step toward regulatory acceptance. Similarly, the FDA has acknowledged zebrafish seizure assays as a useful alternative to the standard rodent model in certain contexts of use.
- OECD test guidelines for zebrafish developmental neurotoxicity (TG 236) are under revision to include behavioral endpoints.
- Zebrafish assays for seizure liability show high concordance with rodent models and human clinical data, offering a potential replacement for the rodent minimal risk test.
- The zebrafish sleep model is being used to evaluate compounds for insomnia and circadian rhythm disorders, with translational endpoints such as total sleep time and fragmentation.
- Anxiety-like behavior assays in zebrafish (e.g., novel tank diving test, light–dark preference) are gaining traction for anxiolytic drug screening.
The regulatory acceptance of zebrafish NAMs is accelerating, driven by the need for faster, more human-relevant safety data. As acceptance criteria become clearer, the adoption of these assays in the pharmaceutical industry is expected to increase.
5Pipeline Outlook and Commercial Adoption
The commercial adoption of NAMs in neuroscience drug development is being driven by a combination of regulatory push, technological advances, and the 3Rs imperative. Large pharmaceutical companies are establishing internal NAMs platforms, while contract research organizations (CROs) are expanding zebrafish service offerings. The market for zebrafish models in drug discovery is projected to grow significantly, with CNS applications representing the fastest-growing segment. Key areas of commercial interest include the use of zebrafish for screening of antisense oligonucleotides and gene therapies, where the whole-organism platform allows evaluation of biodistribution and efficacy in a single system.
- Pharma companies are integrating zebrafish into early screening cascades to reduce attrition before rodent studies.
- CROs now offer validated zebrafish assays for CNS indications, including cognitive impairment, anxiety, depression, and neurodegeneration.
- The integration of zebrafish with other NAMs (e.g., human iPSC-derived neurons) creates a comprehensive pipeline that combines human-specific in vitro data with whole-organism pharmacology.
- Regulatory qualification of zebrafish NAMs for specific contexts of use will further de-risk investment and accelerate adoption.
The pipeline of NAMs in neuroscience is maturing, with zebrafish models playing an increasingly central role. From discovery screening to regulatory acceptance, zebrafish offer a unique combination of throughput, physiological relevance, and ethical alignment with the 3Rs. As the FDA's NAMs framework is implemented, and as more zebrafish assays gain regulatory qualification, the transition from traditional animal testing to a more integrated, human-relevant paradigm will accelerate.